Cristal Therapeutics and iTeos Therapeutics announce strategic partnership

Date: 07/12/2016

7 December 2016, Maastricht, The Netherlands and Gosselies, Belgium –  Cristal Therapeutics and iTeos Therapeutics today announced a strategic partnership for the discovery, development and commercialization of optimized immuno anti-cancer drug candidates, using Cristal Therapeutics’ medicinal nanotechnology CriPec® platform. The initial goal of this partnership is to determine the therapeutic efficacy of targeted drugs using Cristal’s CriPec® application in iTeos’ preclinical models which have been proven to be predictive in combinations of several immune activators – such as IDO1 and TDO2 – with checkpoint inhibitors.

Please find the full press release here.